The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation
- 1 October 2002
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 15 (9-10) , 486-493
- https://doi.org/10.1111/j.1432-2277.2002.tb00204.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- A prospective economic evaluation of basiliximab (Simulect®) therapy following renal transplantationClinical Transplantation, 2000
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed DataPharmacoEconomics, 1998
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- Audit of quality of hospital haemodialysis in ScotlandNephrology Dialysis Transplantation, 1997
- Calcium channel blockers: what they can and what they can't doNephrology Dialysis Transplantation, 1997
- DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION1Transplantation, 1996
- Cost-Effectiveness Studies of Renal TransplantationInternational Journal of Technology Assessment in Health Care, 1995
- An Introduction to the BootstrapPublished by Springer Nature ,1993